Perrigo Company plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Albert A. Manzone
- Full Time Employees
- 8,100
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- The Sharp Building Allegan DU United States D02 TY74
- IPO Date
- Dec 17, 1991
- CIK
- 0001585364
- Website
- perrigo.com
- Similar Companies
- Business
- Perrigo Company plc (NYSE: PRGO) manufactures and distributes a broad portfolio of over-the-counter (OTC) consumer self-care products and pharmaceutical solutions worldwide; its core offerings encompass upper respiratory products including cough suppressants, expectorants, sinus and allergy relief; infant formulas and nutritional beverages in the nutrition segment; digestive health products such as antacids, anti-diarrheals and anti-heartburn remedies; pain and sleep aids; as well as skin care, women's health and oral care items under store-brand private labels and select branded lines; the company additionally supplies active pharmaceutical ingredients and provides contract manufacturing services. Founded in 1887 and headquartered in Dublin, Ireland, Perrigo operates manufacturing facilities and distribution networks across North America, Europe including the UK and Ireland, and select international markets, serving retailers, healthcare providers and consumers seeking affordable health and wellness alternatives. In recent developments, Perrigo signed a binding agreement in 2024 to divest its HRA Pharma Rare Diseases business to ESTEVE for up to €275 million, enhancing focus on core self-care categories; announced the sale of its Dermacosmetics business to Kairos Bidco AB, managed by KKR, for up to €327 million in July 2025; launched new products in nutrition, skin care and women's health categories; initiated Project Energize targeting $140 million to $170 million in annualized pre-tax savings by end-2026; refinanced $1.1 billion in debt including redemption of 4.375% Senior Notes due 2026 and repayment of 3.9% Senior Notes due 2024; and began a strategic review of its infant formula business in November 2025 to optimize cash flows and reassess $240 million in planned investments.
Company News
Perrigo Company plc (PRGO) Q3 2026 Earnings Call Transcript
Perrigo (PRGO) Reports Q3 Earnings: What Key Metrics Have to Say
Perrigo (PRGO) Surpasses Q3 Earnings Estimates
Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations
Perrigo Announces Quarterly Dividend
Perrigo Announces Agreement to Divest Infant Formula Business to MeridianMade
Earnings Preview: Perrigo (PRGO) Q3 Earnings Expected to Decline
Perrigo to Release Third Quarter 2026 Financial Results on November 4, 2026
Perrigo Co PLC (PRGO) Stock Up 3.9% and Still Undervalued -- GF Score: 60/100
Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?
Squarepoint Ops LLC Cuts Position in Perrigo Company plc $PRGO
Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?
Perrigo to Attend the Barclays Global Consumer Conference
PRGO or NEOG: Which Is the Better Value Stock Right Now?
Should Value Investors Buy Perrigo (PRGO) Stock?
My Top 5 Dividend Picks For August
Perrigo: The Rebound Is Just Getting Started
PRGO vs. NEOG: Which Stock Is the Better Value Option?
Are Investors Undervaluing Perrigo (PRGO) Right Now?
Perrigo Q2 Earnings Call Highlights